CA2534316A1 - Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxygenase-1 - Google Patents

Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxygenase-1 Download PDF

Info

Publication number
CA2534316A1
CA2534316A1 CA002534316A CA2534316A CA2534316A1 CA 2534316 A1 CA2534316 A1 CA 2534316A1 CA 002534316 A CA002534316 A CA 002534316A CA 2534316 A CA2534316 A CA 2534316A CA 2534316 A1 CA2534316 A1 CA 2534316A1
Authority
CA
Canada
Prior art keywords
compositions
thromboxane
cyclooxygenase
inhibitor
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002534316A
Other languages
English (en)
French (fr)
Inventor
Hans R. Brunner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
B M R A Corp BV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2534316A1 publication Critical patent/CA2534316A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002534316A 2003-08-07 2004-08-05 Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxygenase-1 Abandoned CA2534316A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49297503P 2003-08-07 2003-08-07
US60/492,975 2003-08-07
PCT/IB2004/002523 WO2005016334A1 (en) 2003-08-07 2004-08-05 Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxigenase-1

Publications (1)

Publication Number Publication Date
CA2534316A1 true CA2534316A1 (en) 2005-02-24

Family

ID=34193159

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002534316A Abandoned CA2534316A1 (en) 2003-08-07 2004-08-05 Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxygenase-1

Country Status (6)

Country Link
US (1) US20050059741A1 (enExample)
EP (1) EP1660076A1 (enExample)
JP (1) JP2007508242A (enExample)
AU (1) AU2004264722A1 (enExample)
CA (1) CA2534316A1 (enExample)
WO (1) WO2005016334A1 (enExample)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK471479A (da) * 1978-12-13 1980-06-14 Pfizer Fremgangsmaade til fremstilling af imidazolderivater og salte deraf
US5100889A (en) * 1989-04-03 1992-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
ZA911453B (en) * 1990-03-19 1991-11-27 Squibb & Sons Inc Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation
GB9220137D0 (en) * 1992-09-23 1992-11-04 Pfizer Ltd Therapeutic agents
JPH0753505A (ja) * 1992-10-01 1995-02-28 Hokuriku Seiyaku Co Ltd ベンゼンスルホンアミド誘導体及びその用途
US5605917A (en) * 1994-12-22 1997-02-25 Bristol-Myers Squibb Company Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US6586458B1 (en) * 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
AU2890899A (en) * 1998-03-13 1999-09-27 Pozen, Inc. Prophylaxis and treatment of migraine headaches with thromboxane synthetase inhibitors and/or receptor antagonists
AU2001264729A1 (en) * 2000-05-22 2001-12-03 Nitromed, Inc. Thromboxane inhibitors, compositions and methods of use related applications
IL160271A0 (en) * 2001-09-19 2004-07-25 Altana Pharma Ag Pharmaceutical compositions containing pde4-inhibitors and nsaid
JP2005533830A (ja) * 2002-07-09 2005-11-10 ビー．エム．アール．エイ． コーポレイション ベスローテン フェンノートシャップ トロンボキサンａ２受容体アンタゴニストおよびｃｏｘ−２阻害剤の薬剤の組み合わせ

Also Published As

Publication number Publication date
WO2005016334A1 (en) 2005-02-24
AU2004264722A1 (en) 2005-02-24
EP1660076A1 (en) 2006-05-31
JP2007508242A (ja) 2007-04-05
US20050059741A1 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
TW200510416A (en) P38 inhibitors and methods of use thereof
MY158162A (en) 5-membered heterocycle-based p38 kinase inhibitors
WO2006044825A3 (en) Mitotic kinesin inhibitors and methods of use thereof
EP1622589A4 (en) COMPOSITIONS, TARGETS, METHODS AND DEVICES FOR THE TREATMENT OF OCULAR AND PERIOCULAR DISORDERS
DE60216516D1 (de) Dynamische neuerteilung des frequenzspektrums
AU2003289888A1 (en) Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
WO2005055932A3 (en) Therapeutic combinations and methods including irm compounds
AU2001264729A1 (en) Thromboxane inhibitors, compositions and methods of use related applications
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
WO2002016416A3 (en) Diagnosis and treatment of cardiovascular conditions
WO2003084560A3 (en) Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
WO2004103283A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
WO2004093813A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
MXPA05012705A (es) Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
WO2006016262A8 (en) Combination of a selective noradrenaline reuptake inhibitor and a pdev inhibitor
WO2002068476A3 (en) Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
WO2004094373A3 (en) A method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
YU57803A (sh) Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja
WO2006100213A8 (en) Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a cox-2 inhibitor
ZA200711041B (en) Topical pain relief compositions of N,2,3-trimethyl-2-isopropylbutamide and methods for using the same
AUPS194902A0 (en) Compositions and methods for diagnosis and treatment of cardiovascular disorders
WO2002009759A3 (en) Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
WO2003061684A3 (en) Tumour treatment compositions comprising hsp70 and tumour necrosis factor

Legal Events

Date Code Title Description
FZDE Discontinued